Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement - Brainstorm Cell (NASDAQ:BCLI)

BrainStorm Cell Therapeutics Inc. BCLI shares crashed 42.74% to $0.67 in after-hours trading on Friday after the company announced its voluntary delisting from the Nasdaq Capital Market.

Original reporting
Benzinga · Mohd Haider
Published Jul 18, 2025, 9:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 18, 2025, 10:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$BCLI
Bearish
high confidence
Mentioned
$BCLI
Relevance
6/10
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$BCLIBearishLow
01

Why it matters

The delisting has caused negative market sentiment and increased volatility for BCLI, with potential ripple effects on biotech sector sentiment.

02

Market read

The event is highly relevant for current and potential investors in BCLI and the biotech sector, indicating caution due to liquidity and regulatory considerations.

03

What to watch

The company's fundamentals, pipeline progress, and financial health need to be evaluated to determine if the delisting is a sign of underlying issues or a strategic repositioning.

Relevance 6/10Timing: short-term

Background

Brainstorm Cell Therapeutics announced its voluntary delisting from Nasdaq, citing strategic reasons, which led to a sharp decline in its stock price.

Company-level read

Ticker impact

$BCLIBearishHigh confidence
Context

The news concerns Brainstorm Cell Therapeutics Inc. (BCLI), which has announced a voluntary delisting from Nasdaq, leading to a significant stock price decline.

Expected impact

Expect continued volatility and potential further decline in the short term; long-term outlook remains uncertain until company fundamentals are clarified.

Evidence & confidence

The immediate and substantial price drop following the delisting announcement reflects strong market reaction, supported by the company's decision to voluntarily delist, which is typically perceived negatively by investors.

Market effects

Potential negative sentiment spillover to the biotech and life sciences sectors, especially for companies with liquidity concerns or delisting risks.

Limited regional impact; primarily affects US-based biotech stocks.

Minimal; the event is specific to a single company's delisting and does not significantly influence global markets.

Counterpoint

The delisting could be a strategic move to reduce regulatory burdens, potentially allowing the company to focus on long-term development without Nasdaq compliance pressures.

Key entities

  • Brainstorm Cell Therapeutics Inc.

    A biotech company focused on developing stem cell therapies for neurodegenerative diseases.

Related articles

$BCLIMed

BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Notice of Pendency and Proposed Settlement of Stockholder

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE BRAINSTORM CELL Lead Case No. 1:24-cv-01095-DEH THERAPEUTICS, INC. DERIVATIVE LITIGATION EXHIBIT C NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE MATTERS TO: ALL RECORD HOLDERS AND

$BCLIMed

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, November 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegener

$BCLIMed

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.

$BCLIMed

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Aug 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerativ

$ORCLMed

Oracle says OpenAI contract is fully funded, addresses market financing scrutiny

Oracle (NYSE:ORCL) announced it has fully funded its cloud infrastructure contract with OpenAI, completing a $20B capital raise plan. The company addressed market scrutiny over financing, reiterating its commitment to positive free cash flow by H2 2028 and $30B annual free cash flow by 2029. Oracle also updated progress on its data center buildout, including sites for OpenAI's AI models.